Latest Period
Q2 2026
Security Snapshot
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) Institutional Ownership
CUSIP: 29842P105
13F Institutional Holders and Ownership History from Q2 2024 to Q2 2026
Institutions Reporting
68
Shares (Excl. Options)
24,811,199
Price
$6.61
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value
- Symbol
- EPRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 24,811,199
- Total 13F value
- $163,631,315
- Portfolio coverage rank
- 0%
- Share change
- +1,496,891
- Value change
- +$9,136,517
- Number of holders
- 68
- Shares outstanding
- 61,607,578
- SEC-reported price per share
- $6.55
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 29842P105.
- 68 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 54 to 68 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $158,258,957 to $163,631,315.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 68 institutions filings for Q2 2026.
Security key
29842P105
Latest holder period
Q2 2026
13F holders
68
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
EPRX full holder history
EUPRAXIA PHARMACEUTICALS INC. SEC filings
EUPRAXIA PHARMACEUTICALS INC. company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29842P105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
EPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Freedman Joseph S. | 9% | -12% | $47,037,881 | +$2,495,500 | 5,843,215 | +5.6% | Joseph S. Freedman | 13 Mar 2026 |
| Beutel, Goodman & Co Ltd. | 8% | $23,947,504 | 4,058,899 | Beutel, Goodman & Co Ltd. | 30 Sep 2025 | |||
| DISBROW ROBERT | 7% | $21,052,085 | 3,568,150 | Robert Disbrow | 30 Sep 2025 | |||
| MANCHESTER MANAGEMENT CO LLC | 4.5% | -40% | $19,184,600 | -$8,600,916 | 2,772,341 | -31% | JAMES E. BESSER | 30 Jun 2026 |
As of 30 Jun 2026, 68 institutional investors reported holding 24,811,199 shares of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX). This represents 40% of the company’s total 61,607,578 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 5.9% | 3,627,864 | -1.1% | 0.18% | $23,806,000 |
| Affinity Asset Advisors, LLC | 2.7% | 1,650,000 | +3.8% | 0.53% | $10,906,500 |
| Balyasny Asset Management L.P. | 2.2% | 1,350,015 | +0% | 0.02% | $8,923,599 |
| Vivo Capital, LLC | 2.2% | 1,350,000 | 0% | 0.81% | $8,923,500 |
| SCOTIA CAPITAL INC. | 2.2% | 1,343,726 | +0.12% | 0.03% | $8,782,272 |
| PFM Health Sciences, LP | 2% | 1,210,661 | +124% | 0.69% | $8,002,469 |
| GREAT POINT PARTNERS LLC | 1.9% | 1,200,000 | 0% | 1.9% | $7,932,000 |
| Jupiter Topco LLC | 1.7% | 1,046,000 | 0% | 0% | $6,851,300 |
| Rubric Capital Management LP | 1.4% | 867,424 | +26% | 0.05% | $5,733,673 |
| Ikarian Capital, LLC | 1.3% | 809,741 | -33% | 0.88% | $5,352,388 |
| Woodline Partners LP | 1.2% | 746,864 | +70% | 0.02% | $4,936,771 |
| Point72 Asset Management, L.P. | 1.2% | 730,284 | -25% | 0.01% | $4,827,716 |
| AMERIPRISE FINANCIAL INC | 1.2% | 711,024 | +9.5% | 0% | $4,699,869 |
| Redmile Group, LLC | 0.99% | 611,400 | -13% | 0.27% | $4,041,354 |
| Seven Fleet Capital Management LP | 0.99% | 610,785 | +41% | 0.67% | $4,037,289 |
| UBS Group AG | 0.84% | 519,211 | -32% | 0% | $3,431,984 |
| CITADEL ADVISORS LLC | 0.81% | 502,011 | +118% | 0% | $3,318,292 |
| MILLENNIUM MANAGEMENT LLC | 0.72% | 441,586 | 0% | $2,918,796 | |
| Alyeska Investment Group, L.P. | 0.61% | 375,000 | 0% | 0.01% | $2,478,750 |
| PICTON MAHONEY ASSET MANAGEMENT | 0.59% | 360,878 | 0.02% | $2,385,404 | |
| Velan Capital Investment Management LP | 0.57% | 352,000 | 0% | 1.4% | $2,326,720 |
| JANE STREET GROUP, LLC | 0.53% | 329,053 | +835% | 0% | $2,157,990 |
| Aisling Capital Management LP | 0.53% | 325,000 | 0% | 0.46% | $2,148,250 |
| SummitTX Capital, L.P. | 0.52% | 318,784 | -2.8% | 0.06% | $2,107,162 |
| ROYAL BANK OF CANADA | 0.51% | 311,435 | +19% | 0% | $2,058,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Latest
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 24,811,199 | $163,631,315 | +$9,136,517 | $6.61 | 68 |
| 2026 Q1 | 22,228,584 | $158,258,957 | +$59,698,825 | $7.24 | 54 |
| 2025 Q4 | 13,830,451 | $104,211,571 | +$5,872,102 | $7.55 | 35 |
| 2025 Q3 | 12,813,323 | $75,287,324 | +$63,953,992 | $5.90 | 27 |
| 2025 Q2 | 1,970,076 | $10,889,810 | -$1,049,985 | $5.76 | 14 |
| 2025 Q1 | 2,167,593 | $7,087,336 | +$1,118,946 | $3.28 | 11 |
| 2024 Q4 | 1,826,270 | $5,634,759 | +$50,501 | $3.17 | 9 |
| 2024 Q3 | 1,798,968 | $4,545,745 | +$185,000 | $2.63 | 8 |
| 2024 Q2 | 1,727,190 | $4,433,025 | +$4,433,025 | $2.58 | 8 |